Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Unicycive Therapeutics, Inc. due to allegations of violations of federal securities laws, particularly concerning misleading statements about the company's compliance with FDA manufacturing requirements and the regulatory prospects of its New Drug Application (NDA) for OLC [3][5]. Group 1: Legal Investigation and Class Action - The firm is reminding investors of the October 14, 2025 deadline to seek the role of lead plaintiff in a federal securities class action against Unicycive [3]. - Investors who suffered losses in Unicycive between March 29, 2024, and June 27, 2025, are encouraged to contact the firm to discuss their legal rights [1][3]. Group 2: Allegations Against Unicycive - The complaint alleges that Unicycive and its executives made false and misleading statements regarding the company's ability to meet FDA manufacturing compliance requirements and the prospects of the OLC NDA [5]. - On June 10, 2025, Unicycive disclosed deficiencies in cGMP compliance at a third-party manufacturing vendor, leading to a stock price drop of $3.68 per share, or 40.89%, closing at $5.32 [6]. - Following a Complete Response Letter from the FDA on June 30, 2025, citing the same cGMP deficiencies, Unicycive's stock fell by $2.03 per share, or 29.85%, closing at $4.77 [7].

LOS ANGELES, Oct. 09, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Unicycive Therapeutics, Inc., (“Unicycive” or the "Company") (NASDAQ: UNCY) investors off a class action on behalf of investors that bought securities between March 29, 2024 and June 27, 2025, inclusive (the “Class Period”). Unicycive investors have until October 14, 2025 to file a lead plaintiff motion. Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: lesley@portnoylaw.com, to discuss ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Unicycive Therapeutics, Inc. due to alleged violations of federal securities laws, with a deadline for investors to seek lead plaintiff status in a class action lawsuit by October 14, 2025 [4]. Group 1: Allegations Against Unicycive - The complaint alleges that Unicycive and its executives made false and misleading statements regarding the company's ability to meet FDA manufacturing compliance requirements and the regulatory prospects of its OLC NDA [6]. - Specific deficiencies in cGMP compliance were identified at a third-party manufacturing vendor, which were not disclosed prior to the FDA's findings [7]. Group 2: Stock Price Impact - Following the announcement of deficiencies on June 10, 2025, Unicycive's stock price fell by $3.68 per share, a decrease of 40.89%, closing at $5.32 per share [7]. - On June 30, 2025, after the FDA issued a Complete Response Letter citing the same deficiencies, the stock price dropped by $2.03 per share, or 29.85%, closing at $4.77 per share [8]. Group 3: Legal Process and Participation - The lead plaintiff in the class action is the investor with the largest financial interest who is also typical of the class members, overseeing the litigation on behalf of the class [9]. - Any member of the class can move to serve as lead plaintiff or remain an absent class member without affecting their ability to share in any recovery [9].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Unicycive Therapeutics, Inc. due to allegations of violations of federal securities laws related to misleading statements about the company's compliance with FDA manufacturing requirements and the regulatory prospects of its New Drug Application (NDA) for OLC [4][6]. Group 1: Legal Investigation and Class Action - The firm is reminding investors of the October 14, 2025 deadline to seek the role of lead plaintiff in a federal securities class action against Unicycive [4]. - Investors who suffered losses in Unicycive between March 29, 2024, and June 27, 2025, are encouraged to contact the firm to discuss their legal rights [1][4]. Group 2: Allegations Against Unicycive - The complaint alleges that Unicycive and its executives made false and misleading statements regarding the company's readiness to meet FDA manufacturing compliance requirements and the prospects of the OLC NDA [6]. - On June 10, 2025, Unicycive disclosed deficiencies in cGMP compliance at a third-party manufacturing vendor, leading to a stock price drop of $3.68 per share, or 40.89%, closing at $5.32 [7]. - Following a Complete Response Letter from the FDA on June 30, 2025, citing the same cGMP deficiencies, Unicycive's stock fell by $2.03 per share, or 29.85%, closing at $4.77 [8].

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Unicycive To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Unicycive between March 29, 2024 and June 27, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330Â (Ext. 1310). [You may also click here for additional information] , /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading ...

Accessibility StatementSkip Navigation Join the case to recover your losses. LOS ANGELES, Oct. 2, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Unicycive Therapeutics, Inc. ("Unicycive" or "the Company") (NASDAQ: UNCY ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of UNCY during the class period listed are encourage ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Unicycive Therapeutics, Inc. due to alleged violations of federal securities laws, with a deadline for investors to seek lead plaintiff status by October 14, 2025 [2][4]. Group 1: Company Overview - Unicycive Therapeutics, Inc. is a company listed on NASDAQ under the ticker UNCY [2]. - The firm Faruqi & Faruqi has a history of recovering hundreds of millions of dollars for investors since its establishment in 1995 [3]. Group 2: Allegations and Stock Performance - The complaint against Unicycive alleges that the company and its executives made false or misleading statements regarding their readiness to meet FDA manufacturing compliance requirements and the regulatory prospects of their OLC NDA [4]. - Following a press release on June 10, 2025, regarding FDA deficiencies, Unicycive's stock price dropped by $3.68 per share, a decline of 40.89%, closing at $5.32 per share [5]. - On June 30, 2025, after the FDA issued a Complete Response Letter citing the same deficiencies, the stock fell by $2.03 per share, or 29.85%, closing at $4.77 per share [6]. Group 3: Legal Proceedings - Investors who suffered losses exceeding $50,000 between March 29, 2024, and June 27, 2025, are encouraged to contact Faruqi & Faruqi to discuss their legal options [1]. - The role of lead plaintiff in the class action is open to any member of the putative class, with the ability to direct and oversee the litigation [7].

Group 1 - The Schall Law Firm has initiated a class action lawsuit against Unicycive Therapeutics, Inc. for violations of the Securities Exchange Act of 1934 [1][4] - The class period for the lawsuit is defined as between March 29, 2024, and June 27, 2025, during which investors are encouraged to participate if they suffered losses [2] - The complaint alleges that Unicycive made false and misleading statements regarding its FDA manufacturing compliance and the likelihood of FDA approval for its treatment OLC [4] Group 2 - Investors are advised to contact the Schall Law Firm to discuss their rights and potential participation in the lawsuit [3] - The class has not yet been certified, meaning that until certification occurs, investors are not represented by an attorney [3] - The Schall Law Firm specializes in securities class action lawsuits and shareholder rights litigation [5]

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Unicycive Therapeutics, Inc. due to allegations of violations of federal securities laws, particularly concerning misleading statements about the company's compliance with FDA manufacturing requirements and the regulatory prospects of its New Drug Application (NDA) for OLC [4][6]. Group 1: Legal Investigation and Claims - The law firm is encouraging investors who suffered losses exceeding $50,000 in Unicycive between March 29, 2024, and June 27, 2025, to contact them for legal options [1]. - There is a deadline of October 14, 2025, for investors to seek the role of lead plaintiff in a federal securities class action against Unicycive [4]. - The complaint alleges that Unicycive and its executives made false and misleading statements regarding the company's readiness to meet FDA manufacturing compliance requirements and the prospects of the OLC NDA [6]. Group 2: Stock Price Impact - Following a press release on June 10, 2025, regarding FDA deficiencies at a third-party manufacturing vendor, Unicycive's stock price fell by $3.68 per share, or 40.89%, closing at $5.32 per share [7]. - On June 30, 2025, after the FDA issued a Complete Response Letter for the OLC NDA due to the same deficiencies, the stock price dropped by $2.03 per share, or 29.85%, closing at $4.77 per share [8]. Group 3: Class Action Participation - The lead plaintiff in a class action is defined as the investor with the largest financial interest who is adequate and typical of class members, overseeing the litigation on behalf of the class [9]. - Any member of the putative class can move the court to serve as lead plaintiff or choose to remain an absent class member without affecting their ability to share in any recovery [9].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Unicycive Therapeutics, Inc. due to allegations of violations of federal securities laws related to misleading statements about the company's compliance with FDA manufacturing requirements and the regulatory prospects of its New Drug Application (NDA) for OLC [4][6]. Group 1: Legal Investigation and Class Action - Faruqi & Faruqi is encouraging investors who suffered losses in Unicycive between March 29, 2024, and June 27, 2025, to discuss their legal rights [1][4]. - There is a deadline of October 14, 2025, for investors to seek the role of lead plaintiff in the federal securities class action against Unicycive [4][9]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [5]. Group 2: Allegations Against Unicycive - The complaint alleges that Unicycive and its executives made false and misleading statements regarding the company's ability to meet FDA manufacturing compliance requirements and the prospects of the OLC NDA [6]. - On June 10, 2025, Unicycive disclosed deficiencies in cGMP compliance at a third-party manufacturing vendor, leading to a stock price drop of $3.68 per share, or 40.89%, closing at $5.32 [7]. - Following a Complete Response Letter from the FDA on June 30, 2025, citing the same cGMP deficiencies, Unicycive's stock fell by $2.03 per share, or 29.85%, closing at $4.77 [8].